Medroxiprogesterona_[Inn-Spanish]

Category

Medroxiprogesterona_[Inn-Spanish]




Useful info

Medroxiprogesterona_[Inn-Spanish] Brand names, Medroxiprogesterona_[Inn-Spanish] Analogs

Medroxiprogesterona_[Inn-Spanish] Brand Names Mixture

  • Lunelle (Medroxyprogesterone + Estradiol)

    • Medroxiprogesterona_[Inn-Spanish] Chemical_Formula

    C22H32O3

    Medroxiprogesterona_[Inn-Spanish] RX_link

    http://www.rxlist.com/cgi/generic/medrox.htm

    Medroxiprogesterona_[Inn-Spanish] fda sheet

    Medroxiprogesterona_[Inn-Spanish] FDA

    Medroxiprogesterona_[Inn-Spanish] msds (material safety sheet)

    Medroxiprogesterona_[Inn-Spanish] Synthesis Reference

    P. Ruggieri, C. Ferrari, U.S. Pat. 3,043,832 (1962)

    Medroxiprogesterona_[Inn-Spanish] Molecular Weight

    344.488 g/mol

    Medroxiprogesterona_[Inn-Spanish] Melting Point

    220 - 223.5 oC

    Medroxiprogesterona_[Inn-Spanish] H2O Solubility

    22.2mg/L

    Medroxiprogesterona_[Inn-Spanish] State

    Solid

    Medroxiprogesterona_[Inn-Spanish] LogP

    3.606

    Medroxiprogesterona_[Inn-Spanish] Dosage Forms

    Tablets; Depo injection

    Medroxiprogesterona_[Inn-Spanish] Indication

    Used as a contraceptive and to treat amenorrhea, abnormal uterine bleeding, endometriosis, endometrial and renal cell carcinomas, and pulmonary disorders such as chronic obstructive pulmonary disease (COPD), Pickwickian syndrome, and other hypercapnic pulmonary conditions.

    Medroxiprogesterona_[Inn-Spanish] Pharmacology

    Medroxyprogesterone is a synthetic progestin more potent than progesterone.

    Medroxiprogesterona_[Inn-Spanish] Absorption

    Rapidly absorbed from GI tract

    Medroxiprogesterona_[Inn-Spanish] Toxicity

    Side effects include loss of bone mineral density, BMD changes in adult women, bleeding irregularities, cancer risks, and thromboembolic disorders.

    Medroxiprogesterona_[Inn-Spanish] Patient Information

    Medroxiprogesterona_[Inn-Spanish] Organisms Affected

    Humans and other mammals